ONECUT2 is a driver of neuroendocrine prostate cancer

Guo, Haiyang; Ci, Xinpei; Ahmed, Musaddeque; T. Hua, Junjie; Soares, Fraser; Lin, Dong; Puca, Loredana; Vosoughi, Aram; Xue, Hui; Li, Estelle; Su, Peiran; Chen, Sujun; Nguyen, Tran; Liang, Yi; Zhang, Yuzhe; Xu, Xin; Xu, Jing; V. Sheahan, Anjali; Ba-Alawi, Wail; Zhang, Si; Mahamud, Osman; N. Vellanki, Ravi; Gleave, Martin; G. Bristow, Robert; Haibe‐Kains, Benjamin; T. Poirier, John; M. Rudin, Charles; Tsao, Ming‐Sound; G. Wouters, Bradly; Fazli, Ladan; Y. Feng, Felix; Ellis, Leigh; van der Kwast, Theodorus; Berlín, Alejandro; Koritzinsky, Marianne; C. Boutros, Paul; Zoubeidi, Amina; Beltran, Himisha; Wang, Yuzhuo; Hansen He, Housheng

doi:10.1038/s41467-018-08133-6

Public

ONECUT2 is a driver of neuroendocrine prostate cancer

Published in Nature Communications • Jan 11, 2019

Authors:

Haiyang Guo

Xinpei Ci

Musaddeque Ahmed

Abstract

Neuroendocrine prostate cancer (NEPC), a lethal form of the disease, is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, which results in resistance to AR-targeted therapy. Clinically, genomically and epigenetically, NEPC resembles other types of ...

Subject

Prostate cancer

Cancer research

Hypoxia (environmental)

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!